Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 10/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474998 | 0.89 | ABCG2 (0.55) | MAP4K4NT5EDPP4ADORA2AADORA1 | |
| SCHEMBL16183524 | 0.82 | MAP4K4 (0.55) | MAP4K4NT5EDPP4ADORA2AADORA1 | |
| SCHEMBL14475168 | 0.82 | PIK3CA (0.49) | MAP4K4ADORA2AADORA1ABCG2 | |
| SCHEMBL16183512 | 0.81 | MAP4K4 (0.49) | MAP4K4NT5EABCG2 | |
| SCHEMBL14475050 | 0.80 | CYP1A2 (0.54) | MAP4K4ADORA2AADORA1ABCG2 | |
| SCHEMBL14475173 | 0.77 | PDE5A (0.49) | ADORA2AADORA1ABCG2 | |
| SCHEMBL14475037 | 0.75 | MEN1 (0.59) | MAP4K4ADORA2AADORA1ABCG2 | |
| SCHEMBL16183518 | 0.75 | HTT (0.54) | NT5EADORA2AADORA1 | |
| SCHEMBL14475085 | 0.75 | WNT1 (0.45) | MAP4K4ADORA2AADORA1ABCG2 | |
| SCHEMBL17803702 | 0.74 | CYP1A2 (0.61) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | MAP4K4 635/4885NT5E 1533/4885DPP4 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.